To assess safety and efficacy of artemisinin-based combination therapies (ACTs) during pregnancy, researchers from the CDC conducted an analysis of the literature which included clinical trials, observational studies, meta-analyses and case reports conducted in Asia and Africa.

Among the women who underwent hysterectomy for uterine fibroids, there was a significant increase in major complications (from 1.9 to 2.4%; adjusted odds ratio, 1.23) and minor complications (from 2.7 to 3.3%; adjusted odds ratio, 1.21).

Compared to the placebo group, the caffeine group performed better in fine motor coordination (P=0.01), visuomotor integration (P<0.05), visual perception (P=0.02), and visuospatial organization (P=0.003).

"Women in plans with the greatest reduction in out-of-pocket cost after mandated coverage of contraception had the greatest gains in IUD insertion," the authors write.

The researchers found that delta-9-tetrahydrocannabinol was detected at low concentrations at all the time points beyond time 0, but no metabolites were detected at any time point.

Compared with both healthy controls and infants exposed to untreated maternal depression, significant gray matter volume expansion was seen in the right amygdala and right insula in SSRI-exposed infants in voxel-based morphometry.

The new Essure labeling restricts the sale and distribution of the device to only health care providers and facilities that provide information to patients about the risks and benefits of this device.

Five factors correlated with breastfeeding behaviors: intentions to breastfeed; belief in the nutritional adequacy and sufficiency of breast milk; belief about others' infant feeding preferences; body image; and social knowledge.

Bonjesta is a multilayer, extended-release formulation that is designed to provide both fast-acting and long-lasting symptom relief.

There were 3.38 cardiovascular hospitalizations per 1,000 person-years for mothers with infants with critical defects, 3.19 for mothers of infants with noncritical defects, and 2.42 for mothers of infants with no heart defects.

No residual effect for past users, including early discontinuers of menopause hormone treatment

The researchers found that concordance of variant calls exceeded 96% between the 2 DNA sources and with parental libraries.

In the trial a personalized engineered autologous tumor cell vaccine was created incorporating rhGM-CSF DNA for enhanced antigen presentation and bifunctional shRNAfurin, which inhibits endogenous immunosuppression.

Bremelanotide is used as needed prior to anticipated sexual activity.

The researchers found that 81% of Pap brush samples from 382 endometrial cancer patients were positive, including 78% with early-stage disease. Among 245 ovarian cancer patients, sensitivity was 33%, including 34% with early-stage disease.

Most women (78.4%) received maternity leave of 6 weeks or less; 72% perceived leave duration as insufficient. For 82.2% of respondents, the American Board of Surgery leave policy was cited as a major barrier to the desired length of leave.

Data added to the labeling includes first-of-their-kind pharmacokinetic studies demonstrating negligible to low transfer of CIMZIA through placenta and minimal transfer to breast milk from mother to infant.

The longitudinal decline in dorsolateral prefrontal cortex volumes was less in the tE2 group compared with the placebo group. In the menopausal hormone therapy groups, the rates of global cognitive change did not differ from that of the placebo group.

Similar reductions were seen for most bothersome symptom severity for all treatment groups over 12 weeks (estradiol, −1.4; moisturizer, −1.2; and placebo, −1.3).

At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.

Suppression of follicle stimulating hormone and luteinizing hormone was reported for all subjects in the P400mg group and 12 of 13 subjects in the C400mg group. No significant change was seen in mood.

Results - measured by the alkaline hematin method - found that at 6 months those in the combination group had 76.2% (P<0.001) clinical response compared to the elagloix along group, in which only 10.1% had a clinical response.

TX-001HR is an investigational treatment for moderate-to-severe vasomotor symptoms due to menopause.

The recall was initiated due to a manufacturing defect.

The researchers identified 5 trials consisting of 194 women. Pooled analysis showed a moderate increase in breast milk volume of 88.3 mL/day with the use of domperidone versus placebo

"Allowing women ad lib oral intake during labor does not increase adverse maternal or neonatal outcomes. It stands to reason that allowing such intake could increase patient satisfaction," the authors write.